ICBP43 cell lines

The ICBP43 panel of 43 breast cancer cell lines represents a diverse set of tumor types. Identical isolates of these cell lines have been distributed to multiple laboratories in the US, and the cells have been profiled extensively at the genomic level.

Below we have provided a table with summary information on these lines including links to their entries in the HMS LINCS Database, subtype classification, and growth conditions. You can also download a spreadsheet version of these data (.xlsx). Furthermore, we have assembled a list of known PTEN and PI3K mutations in these cell lines (.xlsx). (Last update to files and table below: March, 2013)

HMS LINCS has selected the six lines highlighted below in pink (BT-20, Hs 578T, MCF7, MCF 10A, MDA-MB-231, SK-BR-3) as a representative subset for focused profiling and other experimentation.

Name HMS LINCS ID ATCC ID Classification* Transcriptional subtype (Heiser et al. (2012) PNAS) Growth medium Culture conditions
BT-20 50105 HTB-19 TNBC Basal EMEM + 10% FBS + 1% P/S 37.0°C ; 5% CO2
Hs 578T 50238 HTB-126 TNBC Claudin-low DMEM + 0.01 mg/ml bovine insulin + 10% FBS + 1% P/S 37.0°C ; 5% CO2
MCF7 50029 HTB-22 HR+ Luminal DMEM + 10% FBS + 1% P/S 37.0°C ; 5% CO2
MCF 10A 50583 CRL-10317 NM Non-malignant Basal MEBM + 100 ng/ml cholera toxin 37.0°C ; 5% CO2
MDA-MB-231 50058 HTB-26 TNBC Claudin-low Leibovitz’s L-15 +10% FBS + 1% P/S 37.0°C ; No CO2
SK-BR-3 50057 HTB-30 HER2amp HER2+ McCoy’s 5a + 10% FBS + 1% P/S 37.0°C ; 5% CO2
184B5 50576 CRL-8799 TNBC Basal MEBM + 1 ng/ml cholera toxin 37.0°C ; 5% CO2
AU-565 50091 CRL-2351 HER2amp HER2+ RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2
BT-474 50106 HTB-20 HER2amp HER2+ RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2
BT-483 50107 HTB-121 HR+ Luminal RPMI-1640 + 0.01 mg/ml bovine insulin + 20% FBS + 1% P/S 37.0°C ; 5% CO2
BT-549 50108 HTB-122 TNBC Claudin-low RPMI-1640 + 0.023 IU/ml insulin + 10% FBS + 1% P/S 37.0°C ; 5% CO2
CAMA-1 50131 HTB-21 HR+ Luminal EMEM + 10% FBS + 1% P/S 37.0°C ; 5% CO2
DU4475 50577 HTB-123 TNBC RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2
HCC38 50216 CRL-2314 TNBC Claudin-low RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2
HCC70 50219 CRL-2315 TNBC Basal RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2
HCC202 50214 CRL-2316 HER2amp HER2+ RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2
HCC1187 50578 CRL-2322 TNBC Basal RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2
HCC1395 50206 CRL-2324 TNBC Claudin-low RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2
HCC1419 50207 CRL-2326 HER2amp HER2+ RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2
HCC1428 50208 CRL-2327 HR+ Luminal RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2
HCC1500 50579 CRL-2329 HR+ RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2
HCC1569 50210 CRL-2330 HER2amp RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2
HCC1599 50580 CRL-2331 TNBC Basal RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2
HCC1806 50211 CRL-2335 TNBC Basal RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2
HCC1937 50212 CRL-2336 TNBC Basal RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2
HCC1954 50213 CRL-2338 HER2amp HER2+ RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2
HCC2157 50581 CRL-2340 TNBC RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2
HCC2218 50582 CRL-2343 HER2amp HER2+ RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2
MCF 10F 50584 CRL-10318 NM Non-malignant Basal DMEM/F12 (L-glutamine, 15mM Hepes) + 20 ng/ml Human epidermal growth factor + 100 ng/ml cholera toxin + 0.01 mg/ml bovine insulin + 500 ng/ml hydrocortisone (95%) + 5% horse serum 37.0°C ; 5% CO2
MCF-12A 51089 CRL-10782 NM Non-malignant Basal DMEM/F12 (L-glutamine, 15mM Hepes) + 20 ng/ml Human epidermal growth factor + 100 ng/ml cholera toxin + 0.01 mg/ml bovine insulin + 500 ng/ml hydrocortisone (95%) + 5% horse serum 37.0°C ; 5% CO2
MDA-MB-134-VI 50327 HTB-23 HR+ Luminal Leibovitz’s L-15 +10% FBS + 1% P/S 37.0°C ; No CO2
MDA-MB-157 50328 HTB-24 TNBC Claudin-low Leibovitz’s L-15 +10% FBS + 1% P/S 37.0°C ; No CO2
MDA-MB-175-VII 50329 HTB-25 HR+ Luminal Leibovitz’s L-15 +10% FBS + 1% P/S 37.0°C ; No CO2
MDA-MB-361 50331 HTB-27 HER2amp HER2+ Leibovitz’s L-15 +10% FBS + 1% P/S 37.0°C ; No CO2
MDA-MB-415 50332 HTB-128 HR+ Luminal Leibovitz’s L-15 + 10% FBS + 1% P/S + 10 mcg/ml insulin 37.0°C ; No CO2
MDA-MB-436 50333 HTB-130 TNBC Claudin-low Leibovitz’s L-15 + 10% FBS + 1% P/S + 10 mcg/ml insulin 37.0°C ; No CO2
MDA-MB-453 50334 HTB-131 TNBC Luminal Leibovitz’s L-15 +10% FBS + 1% P/S 37.0°C ; No CO2
MDA-MB-468 50335 HTB-132 TNBC Basal Leibovitz’s L-15 +10% FBS + 1% P/S 37.0°C ; No CO2
T47D 50541 HTB-133 HR+ Luminal RPMI-1640 + 0.2 Units/ml bovine insulin + 10% FBS + 1% P/S 37.0°C ; 5% CO2
UACC-812 50556 CRL-1897 HER2amp HER2+ Leibovitz’s L-15 (2 mM L-glutamine) + 20 ng/ml human EGF + 20% FBS + 1% P/S 37.0°C ; No CO2
UACC-893 50557 CRL-1902 HER2amp Luminal Leibovitz’s L-15 +10% FBS + 1% P/S 37.0°C ; No CO2
ZR-75-1 50574 CRL-1500 HR+ Luminal RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2
ZR-75-30 50575 CRL-1504 HER2amp Luminal RPMI-1640 + 10% FBS + 1% P/S 37.0°C ; 5% CO2

* Abbreviations: TNBC = triple negative breast cancer; NM = non-malignant.